Fundraising Fox

株式会社PURMX THERAPEUTICS

Hiroshima, JP · 4 known investors

PURMX Therapeutics develops nucleic acid medicines as anti-cancer drugs based on microRNA research and the concept of an "ageing switch" to induce ageing in cancer cells. The Japanese pharmaceutical venture handles drug development functions including non-clinical research, clinical development, CMC, and regulatory affairs.

BiotechHealthtechLongevityMedical Devices

Founders & leadership

HT
Hidetoshi TaharaCEO/Representative Director and President

Investors · 4

Hiroshima Venture Capital Co. Ltd.Hiroshima
Keio Innovation InitiativeTokyo · $1.5M – $64M
OSAKA University Venture CapitalOsaka · $3M – $142M
UTECTokyo · $3.1M – $78M

Competitors · 1

by search overlap
TradingView3 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.

Companies competing with 株式会社PURMX THERAPEUTICS for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does 株式会社PURMX THERAPEUTICS do?
PURMX Therapeutics develops nucleic acid medicines as anti-cancer drugs based on microRNA research and the concept of an "ageing switch" to induce ageing in cancer cells. The Japanese pharmaceutical venture handles drug development functions including non-clinical research, clinical development, CMC, and regulatory affairs.
Who founded 株式会社PURMX THERAPEUTICS?
株式会社PURMX THERAPEUTICS was founded by Hidetoshi Tahara.
Who are 株式会社PURMX THERAPEUTICS's investors?
株式会社PURMX THERAPEUTICS's investors include Hiroshima Venture Capital Co. Ltd., Keio Innovation Initiative, OSAKA University Venture Capital, UTEC.
Where is 株式会社PURMX THERAPEUTICS headquartered?
株式会社PURMX THERAPEUTICS is headquartered in Hiroshima, JP.